OVID
Income statement / Annual
Last year (2024), Ovid Therapeutics Inc.'s total revenue was $566.00 K,
an increase of 44.39% from the previous year.
In 2024, Ovid Therapeutics Inc.'s net income was -$26.43 M.
See Ovid Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$566.00 K |
$392.00 K |
$1.50 M |
$208.38 M |
$12.62 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$141.73 K
|
$80.31 K
|
$0.00
|
$11.78 K
|
| Gross Profit |
$566.00 K
|
$392.00 K
|
$1.50 M
|
$208.38 M
|
$12.62 M
|
$0.00
|
-$142.00 K
|
-$80.31 K
|
-$56.51 K
|
-$11.78 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$36.77 M
|
$28.59 M
|
$24.62 M
|
$46.94 M
|
$64.12 M
|
$46.86 M
|
$33.79 M
|
$49.97 M
|
$9.59 M
|
$6.61 M
|
| General & Administrative Expenses |
$25.68 M
|
$29.59 M
|
$32.43 M
|
$37.23 M
|
$30.63 M
|
$19.25 M
|
$19.14 M
|
$15.04 M
|
$12.95 M
|
$6.58 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$25.68 M
|
$29.59 M
|
$32.43 M
|
$37.23 M
|
$30.63 M
|
$19.25 M
|
$19.14 M
|
$15.04 M
|
$12.95 M
|
$6.58 M
|
| Other Expenses |
$1.00 K
|
$1.50 M
|
$510.00
|
$1.10 K
|
-$700.00 K
|
-$4.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$62.45 M
|
$59.67 M
|
$57.05 M
|
$84.17 M
|
$94.05 M
|
$61.41 M
|
$52.93 M
|
$65.01 M
|
$22.54 M
|
$13.19 M
|
| Cost And Expenses |
$62.45 M
|
$59.67 M
|
$57.05 M
|
$84.17 M
|
$94.05 M
|
$61.41 M
|
$52.93 M
|
$65.01 M
|
$22.54 M
|
$13.19 M
|
| Interest Income |
$3.90 M
|
$4.90 M
|
$0.00
|
$0.00
|
$395.40 K
|
$948.22 K
|
$952.07 K
|
$201.51 K
|
$0.00
|
$30.28 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$613.00 K
|
$568.00 K
|
$1.38 M
|
$237.08 K
|
$306.85 K
|
$255.00 K
|
$141.73 K
|
$80.31 K
|
$56.51 K
|
$11.78 K
|
| EBITDA |
-$57.77 M |
-$57.01 M |
-$54.17 M |
$124.45 M |
-$81.12 M |
-$61.15 M |
-$52.79 M |
-$64.73 M |
-$22.48 M |
-$13.18 M |
| EBITDA Ratio |
-102.07
|
-145.44
|
-36.04
|
0.6
|
-6.43
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-109.34
|
-151.23
|
-36.96
|
0.6
|
-6.45
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$35.45 M
|
$6.94 M
|
$1.38 M
|
-$45.69 K
|
$395.40 K
|
$948.22 K
|
$952.07 K
|
$201.51 K
|
$120.82 K
|
$30.28 K
|
| Income Before Tax |
-$26.43 M
|
-$52.34 M
|
-$54.17 M
|
$124.16 M
|
-$81.04 M
|
-$60.46 M
|
-$51.98 M
|
-$64.81 M
|
-$22.41 M
|
-$13.16 M
|
| Income Before Tax Ratio |
-46.7
|
-133.52
|
-36.05
|
0.6
|
-6.42
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$1.33 M
|
$0.00
|
$0.00
|
$0.00
|
-$80.31 K
|
-$950.00
|
$0.00
|
| Net Income |
-$26.43 M
|
-$52.34 M
|
-$54.17 M
|
$122.83 M
|
-$81.04 M
|
-$60.46 M
|
-$51.98 M
|
-$64.81 M
|
-$22.41 M
|
-$13.16 M
|
| Net Income Ratio |
-46.7
|
-133.52
|
-36.05
|
0.59
|
-6.42
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.37 |
-0.74 |
-0.77 |
1.78 |
-1.39 |
-1.51 |
-2.11 |
-3.35 |
-1.14 |
-0.67 |
| EPS Diluted |
-0.37 |
-0.74 |
-0.77 |
1.76 |
-1.39 |
-1.51 |
-2.11 |
-3.35 |
-1.14 |
-0.67 |
| Weighted Average Shares Out |
$70.91 M
|
$70.58 M
|
$70.43 M
|
$67.48 M
|
$58.45 M
|
$39.22 M
|
$24.63 M
|
$19.34 M
|
$19.60 M
|
$19.60 M
|
| Weighted Average Shares Out Diluted |
$70.91 M
|
$70.58 M
|
$70.43 M
|
$68.07 M
|
$58.45 M
|
$39.22 M
|
$24.63 M
|
$19.34 M
|
$19.60 M
|
$19.60 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
